SNY
ACCE-researchedSanofi ADS
Healthcare · Drug Manufacturers - General · NASDAQ · United States
$42.50+0.05%
Market cap $101.8BNext earnings 2026-10-30Updated Sep 21, 2026
FAIR VALUE · CONSENSUS
$42.50+0.0%
confidence-weighted across 4 of 6 models
Now $42.50
$42.50
$49.18$134.35
Strong BuySilver65
Price vs fair value
26.4% below
+35.9% to fair value
ACCE score
59
out of 100
Analysts
73% buy
11 covering
P/E
23.0x
forward 8.6x
1-year return
-10.8%
Dividend yield
9.55%
Unlock the ACCE read
INVESTOROverview
⚠ Investor warnings · 3 flags
- highEarnings decline acceleratingEPS down 11.7% YoY with QoQ revenue -7.0%, signaling near-term fundamental deterioration despite 6% annual revenue growth.
- moderateLow momentum scoreMomentum sub-score of 40/100 is notably weak, suggesting poor price action and sentiment relative to peers despite recent ACCE score recovery.
- moderateLarge P/E vs forward gapTrailing P/E 19.2x vs forward 8.4x implies consensus expects a sharp earnings jump; execution risk is high if that recovery doesn't materialize.
Reports in 37 days, last quarter beat by 0.1%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
-9.6% · 1Y
Valuation
INVESTORFull valuation engine INVESTOR FEATURE
Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORQuality and conviction INVESTOR FEATURE
The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
Bullish73% buy · 11 covering analysts
● Strong buy 5● Buy 3● Hold 3● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROSmart money tracking PRO FEATURE
Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 0.0x23.0xhigh 36.4x
ROEbetter than 50% of peers
low -21%6%high 47%
Div yieldbetter than 100% of peers
low 2.1%9.6%high 9.6%
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| SAN.PA | Sanofi | $101.9B | 22.9 | 5.7% | 0.26 | 5.5% | - | Compare |
| GSK.L | GSK | $100.7B | 15.9 | 33.4% | 1.03 | 3.6% | - | Compare |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $100.6B | 15.9 | 33.4% | 1.03 | 3.6% | - | Compare |
| BMY | Bristol-Myers Squibb Company Common Stock | $127.9B | 13.8 | 46.6% | 2.44 | 4.0% | - | Compare |
| PFE | Pfizer Inc. Common Stock | $157.7B | 36.4 | 5.0% | 0.74 | 6.2% | - | Compare |
| GILD | Gilead Sciences Inc. Common Stock | $186.1B | - | -20.7% | 1.10 | 2.1% | - | Compare |
Sector report card
Where SNY ranks against its sector peers on each metric.
Computing percentiles…
News and Record
Reports in 37 days, last quarter beat by 0.1%.
Press releases mentioning this company
- GlobeNewswire•Sep 17, 2026Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic
- GlobeNewswire•Sep 15, 2026Hummingbird Bioscience Appoints Dr. James Garner as President
- GlobeNewswire•Sep 14, 2026Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
14 more press releases · full archive on Investor+.INVESTOR
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.
PRO
Recent performance
1 week
-1.9%
1 month
-7.3%
3 months
+2.2%
6 months
-7.7%
YTD
-12.3%
1 year
-10.8%
SEC filings
40 filings
September 2026
Sep 17
6-KForeign current reportPeriod 2026-09-17
August 2026
Aug 12
Form 4Insider transactionPeriod 2026-08-10
Aug 7
Form 4Insider transactionPeriod 2026-08-06
37 more filings + AI summaries on Investor+.INVESTOR